San Diego-based analytics and public safety company SmartDrive Systems has secured $90 million in funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced Sept. 12 and led by TPG Sixth Street Partners (TSSP).
According to its Crunchbase profile, "SmartDrive Systems gives fleets and drivers unprecedented driving performance insight and analysis, helping save fuel, expenses and lives. Its video analysis, predictive analytics and personalized performance program help fleets improve driving skills, lower operating costs and deliver significant ROI. With an easy-to-use managed service, fleets and drivers can access and self-manage driving performance anytime, anywhere."
The 16-year-old company has raised seven previous funding rounds, including a round in 2017.
SmartDrive's round brings total funding raised by San Diego companies in data and analytics over the past 90 days to $210 million, an increase of $135 million from the previous three-month period. The local data and analytics industry has produced 24 funding rounds over the past year, yielding a total of $497 million in venture funding.
In other local funding news, incubators company ZeaKal announced a $5 million Series C funding round on Sept. 10.
According to Crunchbase, "ZeaKal is a plant science company developed from the incubation pipeline of Kapyon Ventures. The company’s HME technology has been shown to vastly increase the yield and oil content of multiple crops — meaningfully impacting the demand for biomass across food, feed and fuels."
Founded in 2010, the company has raised three previous rounds, including a $10 million corporate round earlier this year.
Meanwhile, biotechnology company LynxBiosciences raised seed funding, announced on Sept. 9. The round was financed by Chorom Pak.
From the company's Crunchbase profile, "LynxBiosciences (LynxBio) is a cytomics company focused on transforming the development of blood cancer therapies and delivering precise patient management by identifying the most promising therapeutic options. Many blood cancers are incurable; the standard of care is empirical treatment, typically through a trial and error process. Our initial focus is multiplemyeloma (MM), whereas patients ultimately relapse and undergo on average 5-7 treatments (ranging from $125,000 to $450,000 p.a.)"
LynxBiosciences last raised non-equity assistance funding in 2018.
This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.
